Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OPKO HealthLTS:0KCS +3.22%58 Debt-to-Equity is 0.33 as of Mar. 2026, which is 83% above its 10-year median of 0.18. GuruFocus rates LTS:0KCS with a GF Score™ of 58/100 and a GF Value™ of $1.06 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 183 Medical Diagnostics & Research companies, OPKO Health ranks worse than 50.27% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for OPKO Health's Debt-to-Equity or its related term are showing as below:
LTS:0KCS'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.05 Med: 0.18 Max: 0.38
Current: 0.33
During the past 13 years, the highest Debt-to-Equity Ratio of OPKO Health was 0.38. The lowest was 0.05. And the median was 0.18.
LTS:0KCS's Debt-to-Equity is ranked worse than 50.27% of 183
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.33
vs LTS:0KCS: 0.33
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
OPKO Health Debt-to-Equity Related Terms
OPKO Health Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for OPKO Health's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0KCS vs PSNL, CDNA, CSTL: Debt-to-Equity Comparison
For the Diagnostics & Research subindustry, OPKO Health's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OPKO Health Debt-to-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, OPKO Health's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where OPKO Health's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OPKO Health (LTS:0KCS) has a Debt-to-Equity of 0.33 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on OPKO Health and its competitors. This is 83% above median its historical median of 0.18. Over the past decade, OPKO Health's Debt-to-Equity has ranged from 0.05 to 0.38. According to the industry distribution chart, OPKO Health ranks #92 out of 183 companies in the Medical Diagnostics & Research industry, placing it in the top 50.3%.
Is OPKO Health's Debt-to-Equity too high?
OPKO Health's current Debt-to-Equity of 0.33 is 83% above median its 10-year median of 0.18. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 0.38. The Medical Diagnostics & Research industry median Debt-to-Equity is 0.33. OPKO Health's value of 0.33 is 0% at this industry median. Based on the distribution chart, OPKO Health ranks #92 out of 183 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, OPKO Health has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OPKO Health's Debt-to-Equity compare to PSNL and CDNA?
According to the Medical Diagnostics & Research industry distribution chart, OPKO Health ranks #92 out of 183 companies for Debt-to-Equity. This places OPKO Health in the lower half of its industry. The industry median Debt-to-Equity is 0.33. OPKO Health's value of 0.33 is 0% at this benchmark. Historically, OPKO Health's own Debt-to-Equity has ranged from 0.05 to 0.38 over the past decade. While the company's 10-year median is 0.18 vs. the industry median of 0.33, OPKO Health has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.33, based on 183 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OPKO Health's current Debt-to-Equity of 0.33 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on OPKO Health and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OPKO Health's current Debt-to-Equity is 0.33, which is 83% above median its own 10-year median of 0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OPKO Health stock overvalued right now?
Based on GuruFocus' analysis, OPKO Health (LTS:0KCS) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.06, compared to a current price of $1.22 — trading 14.9% above its estimated fair value. The current Debt-to-Equity is 0.33, which is 83% above median its 10-year median of 0.18 and 0% at the Medical Diagnostics & Research industry median of 0.33. OPKO Health's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For OPKO Health (LTS:0KCS), the current Debt-to-Equity is 0.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OPKO Health (LTS:0KCS) Overvalued in 2026?
Based on GuruFocus' analysis, OPKO Health stock appears to be overvalued.
The current stock price of $1.22 is trading 14.9% above its estimated GF Value™ of $1.06.
GuruFocus considers OPKO Health to be Modestly Overvalued.
Key valuation signals for LTS:0KCS:
Debt-to-Equity: 0.33 (83% above median its 10-year median of 0.18)
GF Value™: $1.06 vs. price of $1.22 (14.9% above fair value)
Industry Position: 0% at the Medical Diagnostics & Research median (#92 of 183)
No single metric tells the full story. See the LTS:0KCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
58GF Score
Get the complete analysis for LTS:0KCS
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0KCS has been successfully added to your 
